AGT103-T, our HIV therapeutic, is currently in Phase 1 clinical trials. This is the first clinical trial American Gene Technologies® has conducted. However, numerous preclinical trials in animal models as proof of concept. Additionally, one of our preclinical studies has been replicated by NIAID.